Kimia Biosciences: Creating A Centre Of Excellence In Devising Apis, Intermediaries & Formulations

Sameer Goel, CEO & MD

Sameer Goel


The market for active pharmaceutical ingredients was assessed at $209.7 billion in 2021, and from 2022 to 2030, it is anticipated to increase at a compound annual growth rate (CAGR) of 6.0 percent. The development in the production of active pharmaceutical ingredients (APIs) as well as the increased incidence of chronic diseases including cancer and cardiovascular conditions are both responsible for the expansion. Government regulations that are supportive of API manufacturing, together with shifting geopolitical conditions, are further accelerating the market expansion.

This is where Kimia Biosciences has carved a niche for itself in devising demand-driven APIs, Intermediaries and Formulations. In order to provide newer, more innovative, but reasonably priced products across all therapeutic categories, Kimia Biosciences strives to establish itself as a premier destination of the pharmaceutical industry for APIs in India and beyond.

In an exclusive meeting with Pharma Industry Outlook Magazine, Sameer Goel, CEO at Kimia Biosciences walks us through the unique traits of the company.

Give us an overview of Kimia Biosciences. Also take us through its salient features.

Kimia Biosciences is engaged in manufacturing bulk drugs addressing various high potential therapeutic segments. The company has envisaged high growth plans through infrastructure creation and CMS. Kimia has set aside a sizable amount of investment for over the next two years in order to establish itself as a key player in the Indian and international markets.

What are the major differentiating factors that set Kimia Biosciences apart from the players in the space?

We are quick to create and market new products because we focus on the proper product category (niche molecules).We have the capability to offer right from gram scale to multi tonne across different therapeutic segments.We follow the strict standardized procedures and compliance processes in order to guarantee the highest standards of quality. Further, we are an R&D-focused organization supported by a robust mix of people, process and technology. In addition, we have a state-of-the-art manufacturing facility with strong infrastructure in place.

We are committed to upholding the greatest standards of morality, ethics, and quality. Our guiding principles revolve on innovation and excellence, service and customer satisfaction, developing talent and rewarding success, and promoting sustainability to protect the environment.

What has been the approach towards maintaining strict quality standards?

At Kimia Biosciences, we consider it our top priority to ensure customer satisfaction in terms of quality, delivery, and after-sales service. We are devoted to implementing cGMP, upgrading technology, and providing training to effectively adapt to current technologies and high standards in order to continuously raise the quality standards of our products and services. We hold certifications for ISO 14001:2015, ISO 9001:2015, ISO 18001.2007, WHO-GMP, and COPP. We are also acknowledged by the government's Department of Science and Technology And we have proudly received Korean FDA and PIC/S certification.

Our fundamental tenet is that each person bears responsibility for the caliber of his or her own work and should make an ongoing effort to achieve so. We interact with one another in a way that is fair, trustworthy, and respectful while also encouraging participation, honest communication, and teamwork.

We are committed to upholding the greatest standards of ethics, transparency, and honesty. We adhere to local customs and values and put a premium on providing top-notch services

Sameer Goel, CEO & MD

Shed more light on your R&D capabilities.

In order to better meet customer needs and build a strong portfolio for a new wave of therapies, Kimia Biosciences R&D is dedicated to the research and development of improved generic medications. IKimia is committed to making large expenditures in drug research and development so as to provide effective, secure, and cost-efficient medications.

Each scientist at Kimia R&D has access to Sci-finder search tools in their respective laboratories, which are well-equipped for analytical work, synthesis work, and intellectual property. The Analytical Research lab comprises HPLC, GC, GC-HS, Auto-Titrator, Polarimeter, UV spectrophotometer, IR spectrophotometer, and so on.

Each scientist has a dedicated chamber in the synthetic lab, which is equipped with vacuum systems, cooling units, mechanical and magnetic stirrers, Rota Vapors, and air dryers. Impurity profiling for APIs, the development of analytical methods and their validations, specifications from raw materials to finished non-pharmacopoeia products, and accelerated and real-time stability studies are all made possible by the instrumentation, scientific knowledge base, and analytical knowledge base at the R&D Center. The expertise of R&D teams covers products across various therapeutic categories including Ant diabetics & Anti-hypertensive.

Walk us through the vision and mission of the company. What would be the future road of the company, going forward?

Being a prominent pharmaceutical firm with a global presence, consistently providing high-quality medications at reasonable prices, and pledging to serve humanity by upholding its social and environmental obligations. become one of the finest pharmaceutical firms, our focus would be towards garnering our commitment to the development and production of safe, ground-breaking, and affordable medicines with the ultimate goals of enhancing quality of life, easing disease, and serving society as a whole.

We hope to become India's most admired pharmaceutical firm thanks to our wide selection of high-quality, reasonably priced products, ethical business and marketing strategies. We are committed to upholding the greatest standards of ethics, transparency, and honesty. We adhere to local customs and values and put a premium on providing top-notch services.

As we go toward vertical integration, we have plans to establish our own FFF facilities for lifestyle segments in accordance with global regulatory standards so that we can launch ourselves not only in ROW but also in advanced countries in the future. We want to be a great place to work, grow a network of suppliers and customers, and give back to the community.